These two markers usually have been used to approve a prostatic tumor origin (15); however, they are not expressed uniformly in poorly differentiated Prostatic Cancer and might be negative in up to 27% for PSA and 19% of cases for PAP (16). This evidence concerns the gene KLK3 and prostate carcinoma.